LifeScience Clinical & Diagnostic
Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery
Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...
November 11, 2026 | News
Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...
November 10, 2026 | News
China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...
November 09, 2026 | News
NUHS, Singtel and Ericsson Expand Partnership to Advance AI-Enabled Healthcare and 6G Research
Extended collaboration will accelerate research and development in advanced connectivity and emerging 5G Advanced & future 6G tec...
November 05, 2026 | News
Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...
November 05, 2026 | News
Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...
November 02, 2026 | News
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...
October 30, 2026 | News
Kelun-Biotech Secures China NMPA Review for Sac-TMT and Pembrolizumab Combination in First-Line Lung Cancer
This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen o...
October 29, 2026 | News
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours
TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading pro...
October 28, 2026 | News
HanchorBio and Aston Sci Join Forces to Advance Dual-Action Cancer Immunotherapy Targeting Solid Tumours
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
October 27, 2026 | News
Tairex Unveils AI-Powered Agent Hospital Ecosystem to Transform Multidisciplinary Clinical Decision-Making
Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, unveiled the Multidisciplinar...
October 27, 2026 | News
Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...
October 22, 2026 | News
Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration
Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...
October 22, 2026 | News
Ascletis Reports Promising Preclinical Data for Once-Weekly Oral Obesity Treatments, Advances US Phase 1 Trial
Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combina...
October 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
